Astragaloside IV Stimulates Angiogenesis and Increases Nitric Oxide Accumulation Via JAK2/STAT3 and ERK1/2 Pathway

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2013 Oct 19

PMID 24135938

Citations 34

Authors

Shi-Guang Wang

Yan Xu

Jian-Dong Chen

Chuan-Hua Yang

Xiao-Hu Chen

Affiliations

Soon will be listed here.

Abstract

Astragaloside IV (AS-IV), one of the major active constituents of Astragalus membranaceus in Traditional Chinese Medicine, has been widely used to treat ischemic diseases. However, the potential mechanism is this action is unclear. In this study, we tested the hypothesis that AS-IV might promote angiogenesis through multiple signaling pathways. Our data indicate that AS-IV treatment promotes umbilical vein endothelial cells (HUVEC) proliferation, migration, and tube formation. AS-IV treatment also activates JAK2/STAT3 and ERK1/2 signaling pathways, and up-regulates endothelial nitric oxide synthase (eNOS) expression and nitric oxide (NO) production. AS-IV-induced angiogenesis in HUVECs is significantly blocked by specific kinase inhibitors. Our study indicated that AS-IV is a key regulator of NO and angiogenesis through the JAK2/STAT3 and ERK1/2 pathways, which provides a mechanistic basis for the potential use of this compound in the treatment of clinical ischemic diseases.

Citing Articles

Astragaloside IV ameliorates pressure overload-induced heart failure by enhancing angiogenesis through HSF1/VEGF pathway.

Du P, Xu L, Wang Y, Jiao T, Cheng J, Zhang C Heliyon. 2024; 10(17):e37019.

PMID: 39296120 PMC: 11408759. DOI: 10.1016/j.heliyon.2024.e37019.

Effect of Astragaloside IV on improving cardiac function in rats with heart failure: a preclinical systematic review and meta-analysis.

Zhang Z, Zhang M, Xu Y, Lu M, Zhang L, Li C Front Pharmacol. 2023; 14:1226008.

PMID: 37854719 PMC: 10579795. DOI: 10.3389/fphar.2023.1226008.

Review on the protective mechanism of astragaloside IV against cardiovascular diseases.

Yang C, Pan Q, Ji K, Tian Z, Zhou H, Li S Front Pharmacol. 2023; 14:1187910.

PMID: 37251311 PMC: 10213926. DOI: 10.3389/fphar.2023.1187910.

Efficacy of traditional Chinese medicine injection for diabetic kidney disease: A network meta analysis and systematic review.

Long C, Feng H, Liu Z, Li Z, Liu J, Jiang Y Front Pharmacol. 2023; 14:1028257.

PMID: 36874023 PMC: 9981802. DOI: 10.3389/fphar.2023.1028257.

Astragaloside IV attenuate MI-induced myocardial fibrosis and cardiac remodeling by inhibiting ROS/caspase-1/GSDMD signaling pathway.

Zhang X, Qu H, Yang T, Liu Q, Zhou H Cell Cycle. 2022; 21(21):2309-2322.

PMID: 35770948 PMC: 9586672. DOI: 10.1080/15384101.2022.2093598.

References

Li M, Qu Y, Zhao Z, Wu S, Liu Y, Wei X . Astragaloside IV protects against focal cerebral ischemia/reperfusion injury correlating to suppression of neutrophils adhesion-related molecules. Neurochem Int. 2012; 60(5):458-65. DOI: 10.1016/j.neuint.2012.01.026. View

Zachary I, Morgan R . Therapeutic angiogenesis for cardiovascular disease: biological context, challenges, prospects. Heart. 2010; 97(3):181-9. DOI: 10.1136/hrt.2009.180414. View

Bartoli M, Platt D, Lemtalsi T, Gu X, Brooks S, Marrero M . VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J. 2003; 17(11):1562-4. DOI: 10.1096/fj.02-1084fje. View

Nikol S, Baumgartner I, Van Belle E, Diehm C, Visona A, Capogrossi M . Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther. 2008; 16(5):972-8. DOI: 10.1038/mt.2008.33. View

Luo Y, Qin Z, Hong Z, Zhang X, Ding D, Fu J . Astragaloside IV protects against ischemic brain injury in a murine model of transient focal ischemia. Neurosci Lett. 2004; 363(3):218-23. DOI: 10.1016/j.neulet.2004.03.036. View

Henry T, Annex B, McKendall G, Azrin M, Lopez J, Giordano F . The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation. 2003; 107(10):1359-65. DOI: 10.1161/01.cir.0000061911.47710.8a. View

Yu J, deMuinck E, Zhuang Z, Drinane M, Kauser K, Rubanyi G . Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc Natl Acad Sci U S A. 2005; 102(31):10999-1004. PMC: 1182413. DOI: 10.1073/pnas.0501444102. View

Liang C, Park A, Guan J . In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007; 2(2):329-33. DOI: 10.1038/nprot.2007.30. View

Chen X, Meng D, Feng L, Bian Y, Li P, Yang D . Protective effect of astragalosides on myocardial injury by isoproterenol in SD rats. Am J Chin Med. 2006; 34(6):1015-25. DOI: 10.1142/S0192415X0600448X. View

10.

Lamy S, Lachambre M, Lord-Dufour S, Beliveau R . Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vascul Pharmacol. 2010; 53(5-6):200-8. DOI: 10.1016/j.vph.2010.08.002. View

11.

Chen Z, Han Z . STAT3: a critical transcription activator in angiogenesis. Med Res Rev. 2007; 28(2):185-200. DOI: 10.1002/med.20101. View

12.

Iwasaki H, Kawamoto A, Tjwa M, Horii M, Hayashi S, Oyamada A . PlGF repairs myocardial ischemia through mechanisms of angiogenesis, cardioprotection and recruitment of myo-angiogenic competent marrow progenitors. PLoS One. 2011; 6(9):e24872. PMC: 3182165. DOI: 10.1371/journal.pone.0024872. View

13.

Zhang W, Chen H, Zhang C, Liu R, Li H, Chen H . Astragaloside IV from Astragalus membranaceus shows cardioprotection during myocardial ischemia in vivo and in vitro. Planta Med. 2006; 72(1):4-8. DOI: 10.1055/s-2005-873126. View

14.

Zhang W, Hufnagl P, Binder B, Wojta J . Antiinflammatory activity of astragaloside IV is mediated by inhibition of NF-kappaB activation and adhesion molecule expression. Thromb Haemost. 2003; 90(5):904-14. DOI: 10.1160/TH03-03-0136. View

15.

Zhang Y, Hu G, Li S, Li Z, Lam C, Hong S . Pro-angiogenic activity of astragaloside IV in HUVECs in vitro and zebrafish in vivo. Mol Med Rep. 2011; 5(3):805-11. DOI: 10.3892/mmr.2011.716. View

16.

Merchan J, Chan B, Kale S, Schnipper L, Sukhatme V . In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril. J Natl Cancer Inst. 2003; 95(5):388-99. DOI: 10.1093/jnci/95.5.388. View

17.

Zhang L, Liu Q, Lu L, Zhao X, Gao X, Wang Y . Astragaloside IV stimulates angiogenesis and increases hypoxia-inducible factor-1α accumulation via phosphatidylinositol 3-kinase/Akt pathway. J Pharmacol Exp Ther. 2011; 338(2):485-91. DOI: 10.1124/jpet.111.180992. View

18.

Zhang R, Wang L, Zhang L, Chen J, Zhu Z, Zhang Z . Nitric oxide enhances angiogenesis via the synthesis of vascular endothelial growth factor and cGMP after stroke in the rat. Circ Res. 2003; 92(3):308-13. DOI: 10.1161/01.res.0000056757.93432.8c. View

19.

Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C . Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest. 1998; 101(11):2567-78. PMC: 508846. DOI: 10.1172/JCI1560. View

20.

Feliers D, Chen X, Akis N, Ghosh Choudhury G, Madaio M, Kasinath B . VEGF regulation of endothelial nitric oxide synthase in glomerular endothelial cells. Kidney Int. 2005; 68(4):1648-59. DOI: 10.1111/j.1523-1755.2005.00575.x. View